Journal of Yeungnam Medical Science

Yeungnam University College of Medicine, Yeungnam University Institute Medical Science (영남대 의대 학술지 편집위원회)
권호 표지
DOI QR코드

DOI QR Code

Usefulness of presepsin in predicting the prognosis of patients with sepsis or septic shock: a retrospective cohort study

  • Koh, Jeong Suk (Department of Pulmonary and Critical Care Medicine, Chungnam National University School of Medicine) ;
  • Kim, Yoon Joo (Department of Pulmonary and Critical Care Medicine, Chungnam National University School of Medicine) ;
  • Kang, Da Hyun (Department of Pulmonary and Critical Care Medicine, Chungnam National University School of Medicine) ;
  • Lee, Jeong Eun (Department of Pulmonary and Critical Care Medicine, Chungnam National University School of Medicine) ;
  • Lee, Song-I (Department of Pulmonary and Critical Care Medicine, Chungnam National University School of Medicine)
  • Received : 2021.03.19
  • Accepted : 2021.05.12
  • Published : 2021.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The diagnosis and prediction of prognosis are important in patients with sepsis, and presepsin is helpful. In this study, we aimed to examine the usefulness of presepsin in predicting the prognosis of sepsis in Korea. Methods: Patients diagnosed with sepsis according to the sepsis-3 criteria were recruited into the study and classified into surviving and non-surviving groups based on in-hospital mortality. A total of 153 patients (32 and 121 patients with sepsis and septic shock, respectively) were included from July 2019 to August 2020. Results: Among the 153 patients with sepsis, 91 and 62 were in the survivor and non-survivor groups, respectively. Presepsin (p=0.004) and lactate (p=0.003) levels and the sequential organ failure assessment (SOFA) score (p<0.001) were higher in the non-survivor group. Receiver operating characteristic curve analysis revealed poor performances of presepsin and lactate in predicting the prognosis of sepsis (presepsin: area under the curve [AUC]=0.656, p=0.001; lactate: AUC=0.646, p=0.003). The SOFA score showed the best performance, with the highest AUC value (AUC=0.751, p<0.001). The prognostic cutoff point for presepsin was 1,176 pg/mL. Presepsin levels higher than 1,176 pg/mL (odds ratio [OR], 3.352; p<0.001), higher lactate levels (OR, 1.203; p=0.003), and higher SOFA score (OR, 1.249; p<0.001) were risk factors for in-hospital mortality. Conclusion: Presepsin levels were higher in non-survivors than in survivors. Thus, presepsin may be a valuable biomarker in predicting the prognosis of sepsis.

Keywords

References

  1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315:801-10. https://doi.org/10.1001/jama.2016.0287
  2. Kim JH, Hong SK, Kim KC, Lee MG, Lee KM, Jung SS, et al. Influence of full-time intensivist and the nurse-to-patient ratio on the implementation of severe sepsis bundles in Korean intensive care units. J Crit Care 2012;27:414.
  3. Park DW, Chun BC, Kim JM, Sohn JW, Peck KR, Kim YS, et al. Epidemiological and clinical characteristics of community-acquired severe sepsis and septic shock: a prospective observational study in 12 university hospitals in Korea. J Korean Med Sci 2012;27:1308-14. https://doi.org/10.3346/jkms.2012.27.11.1308
  4. Annane D, Siami S, Jaber S, Martin C, Elatrous S, Declere AD, et al. Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. JAMA 2013;310:1809-17. https://doi.org/10.1001/jama.2013.280502
  5. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77. https://doi.org/10.1056/NEJMoa010307
  6. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 2013;41:1167-74. https://doi.org/10.1097/CCM.0b013e31827c09f8
  7. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014;311:1308-16. https://doi.org/10.1001/jama.2014.2637
  8. Brodska H, Valenta J, Pelinkova K, Stach Z, Sachl R, Balik M, et al. Diagnostic and prognostic value of presepsin vs. established biomarkers in critically ill patients with sepsis or systemic inflammatory response syndrome. Clin Chem Lab Med 2018;56:658-68. https://doi.org/10.1515/cclm-2017-0839
  9. Mihajlovic D, Brkic S, Uvelin A, Draskovic B, Vrsajkov V. Use of presepsin and procalcitonin for prediction of SeptiFast results in critically ill patients. J Crit Care 2017;40:197-201. https://doi.org/10.1016/j.jcrc.2017.04.008
  10. Kweon OJ, Choi JH, Park SK, Park AJ. Usefulness of presepsin (sCD14 subtype) measurements as a new marker for the diagnosis and prediction of disease severity of sepsis in the Korean population. J Crit Care 2014;29:965-70. https://doi.org/10.1016/j.jcrc.2014.06.014
  11. Zhang X, Liu D, Liu YN, Wang R, Xie LX. The accuracy of presepsin (sCD14-ST) for the diagnosis of sepsis in adults: a meta-analysis. Crit Care 2015;19:323. https://doi.org/10.1186/s13054-015-1032-4
  12. Zou Q, Wen W, Zhang XC. Presepsin as a novel sepsis biomarker. World J Emerg Med 2014;5:16-9. https://doi.org/10.5847/wjem.j.issn.1920-8642.2014.01.002
  13. Okamura Y. Usefulness of presepsin measurement: a new biomarker for sepsis. Rinsho Byori 2015;63:62-71.
  14. Zhang J, Hu ZD, Song J, Shao J. Diagnostic value of presepsin for sepsis: a systematic review and meta-analysis. Medicine (Baltimore) 2015;94:e2158. https://doi.org/10.1097/MD.0000000000002158
  15. Hassan EA, Abdel Rehim AS, Ahmed AO, Abdullahtif H, Attia A. Clinical value of presepsin in comparison to hsCRP as a monitoring and early prognostic marker for sepsis in critically ill patients. Medicina (Kaunas) 2019;55:36. https://doi.org/10.3390/medicina55020036
  16. Kondo Y, Umemura Y, Hayashida K, Hara Y, Aihara M, Yamakawa K. Diagnostic value of procalcitonin and presepsin for sepsis in critically ill adult patients: a systematic review and meta-analysis. J Intensive Care 2019;7:22. https://doi.org/10.1186/s40560-019-0374-4
  17. Ali FT, Ali MA, Elnakeeb MM, Bendary HN. Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis. Clin Chim Acta 2016;460:93-101. https://doi.org/10.1016/j.cca.2016.06.030
  18. Wen MY, Huang LQ, Yang F, Ye JK, Cai GX, Li XS, et al. Presepsin level in predicting patients' in-hospital mortality from sepsis under sepsis-3 criteria. Ther Clin Risk Manag 2019;15:733-9. https://doi.org/10.2147/TCRM.S209710
  19. Yang HS, Hur M, Yi A, Kim H, Lee S, Kim SN. Prognostic value of presepsin in adult patients with sepsis: systematic review and meta-analysis. PLoS One 2018;13:e0191486. https://doi.org/10.1371/journal.pone.0191486
  20. Yunus I, Fasih A, Wang Y. The use of procalcitonin in the determination of severity of sepsis, patient outcomes and infection characteristics. PLoS One 2018;13:e0206527. https://doi.org/10.1371/journal.pone.0206527
  21. Yu G, Yoo SJ, Lee SH, Kim JS, Jung S, Kim YJ, et al. Utility of the early lactate area score as a prognostic marker for septic shock patients in the emergency department. Acute Crit Care 2019;34:126-32. https://doi.org/10.4266/acc.2018.00283
  22. Larsen FF, Petersen JA. Novel biomarkers for sepsis: a narrative review. Eur J Intern Med 2017;45:46-50. https://doi.org/10.1016/j.ejim.2017.09.030
  23. Zhang Y, Khalid S, Jiang L. Diagnostic and predictive performance of biomarkers in patients with sepsis in an intensive care unit. J Int Med Res 2019;47:44-58. https://doi.org/10.1177/0300060518793791
  24. Giavarina D, Carta M. Determination of reference interval for presepsin, an early marker for sepsis. Biochem Med (Zagreb) 2015;25:64-8. https://doi.org/10.11613/BM.2015.007
  25. Jereb M, Mavric M, Skvarc M, Drobnic A, Dolenc S, Strunjas NP, et al. Usefulness of presepsin as diagnostic and prognostic marker of sepsis in daily clinical practice. J Infect Dev Ctries 2019;13:1038-44. https://doi.org/10.3855/jidc.11764
  26. Masson S, Caironi P, Spanuth E, Thomae R, Panigada M, Sangiorgi G, et al. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. Crit Care 2014;18:R6. https://doi.org/10.1186/cc13183
  27. Liu B, Chen YX, Yin Q, Zhao YZ, Li CS. Diagnostic value and prognostic evaluation of Presepsin for sepsis in an emergency department. Crit Care 2013;17:R244. https://doi.org/10.1186/cc13070
  28. Kim H, Hur M, Moon HW, Yun YM, Di Somma S; GREAT Network. Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis. Ann Intensive Care 2017;7:27. https://doi.org/10.1186/s13613-017-0252-y
  29. Carpio R, Zapata J, Spanuth E, Hess G. Utility of presepsin (sCD14-ST) as a diagnostic and prognostic marker of sepsis in the emergency department. Clin Chim Acta 2015;450:169-75. https://doi.org/10.1016/j.cca.2015.08.013
  30. Zhu Y, Li X, Guo P, Chen Y, Li J, Tao T. The accuracy assessment of presepsin (sCD14-ST) for mortality prediction in adult patients with sepsis and a head-to-head comparison to PCT: a meta-analysis. Ther Clin Risk Manag 2019;15:741-53. https://doi.org/10.2147/TCRM.S198735